The cytoplasmic truncated receptor tyrosine kinase ALK‐ homodimer immortalizes and cooperates with ras in cellular transformation

Anaplastic large‐cell lymphomas are highly associated with a chromosomal translocation t(2;5). This condition results in a chimeric protein NPM/ALK (nucleophosmin/anaplastic lymphoma kinase), in which the shuttle protein NPM is fused to the catalytic domain of the tyrosine receptor kinase ALK. Because the oncogenic potential of NPM/ALK is not well understood, we analyzed the effects of NPM/ALK and the specific contribution of ALK in a standardized cell culture system by using primary rat embryo cells (REC) as cellular targets. We demonstrate by several biological parameters that NPM/ALK is an immortalizing oncogene that provides unlimited, yet normal, growth potential to REC and, with cooperation with a c‐H‐ras oncogene, induces cellular transformation. Targeting NPM/ALK to the nucleus diminishes its oncogenicity, which indicates that the fusion protein exerts its action mainly in the cytoplasm. Expression of the mere catalytic domain of ALK is insufficient with regard to immortalization and transformation. However, reestablishing the potential of ALK to homodimerize by fusing the bacterial dimerization domain of the tetracycline repressor to ALK reenforces the immortalizing function. Collaboration of dimeric ALK with c‐H‐ras converted primary REC into aggressively growing tumor cell lines. These studies identify ALK as a new member of immortalizing oncoproteins that exerts its function within the cytoplasm.

[1]  M. Werner,et al.  Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas , 2000, Leukemia.

[2]  K. Pulford,et al.  Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). , 2000, Blood.

[3]  K. Pulford,et al.  Expression of the ALK tyrosine kinase gene in neuroblastoma. , 2000, The American journal of pathology.

[4]  D. Beach,et al.  p16INK4A and p19ARF act in overlapping pathways in cellular immortalization , 2000, Nature Cell Biology.

[5]  M. Ladanyi,et al.  ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). , 2000, The American journal of pathology.

[6]  A. Rosenwald,et al.  TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. , 1999, Blood.

[7]  Robert A. Weinberg,et al.  Creation of human tumour cells with defined genetic elements , 1999, Nature.

[8]  A. Rosenwald,et al.  Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma. , 1999, The American journal of pathology.

[9]  C. Moskaluk,et al.  Activating c-kit gene mutations in human germ cell tumors. , 1999, The American journal of pathology.

[10]  K. Pulford,et al.  A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. , 1999, Blood.

[11]  L. Chin,et al.  Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation , 1999, Oncogene.

[12]  J. Nevins,et al.  Ras enhances Myc protein stability. , 1999, Molecular cell.

[13]  S. Morris,et al.  Nucleophosmin-Anaplastic Lymphoma Kinase of Large-Cell Anaplastic Lymphoma Is a Constitutively Active Tyrosine Kinase That Utilizes Phospholipase C-γ To Mediate Its Mitogenicity , 1998, Molecular and Cellular Biology.

[14]  G. Evan,et al.  Traps to catch unwary oncogenes. , 1998, Trends in genetics : TIG.

[15]  N. Mckern,et al.  Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor , 1998, Nature.

[16]  A. Rosenwald,et al.  Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: Infrequent detection of the t(2;5) in extranodal lymphomas , 1998, Genes, chromosomes & cancer.

[17]  D. Birnbaum,et al.  Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Morris,et al.  The t(2;5) in human lymphomas. , 1998, Leukemia & lymphoma.

[19]  S. Pileri,et al.  ALK-positive lymphoma: a single disease with a broad spectrum of morphology. , 1998, Blood.

[20]  K. Pulford,et al.  Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. , 1998, Cancer research.

[21]  T. Möröy,et al.  Malignant transformation by cyclin E and Ha-Ras correlates with lower sensitivity towards induction of cell death but requires functional Myc and CDK4 , 1997, Oncogene.

[22]  E. Campo,et al.  The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. , 1997, The American journal of pathology.

[23]  J. Bartek,et al.  Mutual requirement of CDK4 and Myc in malignant transformation: evidence for cyclin D1/CDK4 and p16INK4A as upstream regulators of Myc , 1997, Oncogene.

[24]  C. Naeve,et al.  ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) , 1997, Oncogene.

[25]  K. Pulford,et al.  Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis , 1997, Molecular and cellular biology.

[26]  S. Pileri,et al.  Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type. , 1997, The American journal of pathology.

[27]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[28]  P. Brousset,et al.  A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. , 1997, Blood.

[29]  K. Pulford,et al.  Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. , 1997, Blood.

[30]  F. Spagnoli,et al.  Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes , 1997, The EMBO journal.

[31]  T. Arakawa,et al.  Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system , 1997, Oncogene.

[32]  J. Downing,et al.  Non-Hodgkin's lymphoma in childhood. , 1996, The New England journal of medicine.

[33]  W. Chan,et al.  Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma. , 1996, Blood.

[34]  M. Castellazzi,et al.  Stepwise transformation of rat embryo fibroblasts: c-Jun, JunB, or JunD can cooperate with Ras for focus formation, but a c-Jun-containing heterodimer is required for immortalization , 1996, Molecular and cellular biology.

[35]  H. Satoh,et al.  Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  H. Kovar,et al.  NPM/ALK gene fusion transcripts identify a distinct subgroup of null type Ki‐1 positive anaplastic large cell lymphomas , 1996, British journal of haematology.

[37]  S. Mori,et al.  Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. , 1995, Leukemia.

[38]  M. Hung,et al.  Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. , 1995, Cancer research.

[39]  C. Seelos,et al.  Differential effects by Mad and Max on transformation by cellular and viral oncoproteins. , 1995, Oncogene.

[40]  M. Gossen,et al.  Transcriptional activation by tetracyclines in mammalian cells. , 1995, Science.

[41]  J. Downing,et al.  Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction. , 1995, Blood.

[42]  H. Frierson,et al.  Low frequency association of the t(2;5)(p23;q35) chromosomal translocation with CD30+ lymphomas from American and Asian patients. A reverse transcriptase-polymerase chain reaction study. , 1995, The American journal of pathology.

[43]  H. Satoh,et al.  Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. , 1994, Oncogene.

[44]  W. Saenger,et al.  Structure of the Tet repressor-tetracycline complex and regulation of antibiotic resistance. , 1994, Science.

[45]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[46]  I. Summerhayes,et al.  Immortalization and neoplastic transformation of normal rat colon epithelium: an in vitro model of colonic neoplastic progression. , 1993, Gastroenterology.

[47]  H. Knecht,et al.  Expression of human recombination activating genes (RAG‐1 and RAG‐2) in angioimmunoblastic lymphadenopathy and anaplastic large cell lymphoma of T‐type , 1993, British journal of haematology.

[48]  P. Vigier,et al.  Cooperation between the H-ras oncogene and a truncated derivative of the v-myb oncogene in transformation of hamster embryo fibroblasts. , 1992, Oncogene.

[49]  I. Hay,et al.  Evidence for DNA binding activity of numatrin (B23), a cell cycle-regulated nuclear matrix protein. , 1990, Biochimica et biophysica acta.

[50]  C. Cerni,et al.  Immortalization of primary rat embryo cells by human papillomavirus type 11 DNA is enhanced upon cotransfer of ras. , 1990, Virology.

[51]  D. Lowy,et al.  Successive steps in the process of immortalization identified by transfer of separate bovine papillomavirus genes into rat fibroblasts. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[52]  C. Lehner,et al.  Major nucleolar proteins shuttle between nucleus and cytoplasm , 1989, Cell.

[53]  Qing-Rong Liu,et al.  Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. , 1989, Biochemistry.

[54]  C. Cerni,et al.  Elevated expression of an exogenous c-myc gene is insufficient for transformation and tumorigenic conversion of established fibroblasts. , 1987, Oncogene.

[55]  T. Jenuwein,et al.  Structure-function analysis of fos protein: A single amino acid change activates the immortalizing potential of v-fos , 1987, Cell.

[56]  Robert A. Weinberg,et al.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes , 1983, Nature.

[57]  C. Cerni,et al.  Telomeres, telomerase, and myc. An update. , 2000, Mutation research.

[58]  A. van der Eb,et al.  E1A + cHa-ras transformed rat embryo fibroblast cells are characterized by high and constitutive DNA binding activities of AP-1 dimers with significantly altered composition. , 1999, Gene expression.

[59]  D. Birnbaum,et al.  Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[60]  M. Henriksson,et al.  Proteins of the Myc network: essential regulators of cell growth and differentiation. , 1996, Advances in cancer research.

[61]  H. Satoh,et al.  Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. , 1995, Blood.

[62]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[63]  C. Cerni,et al.  Tumorigenic transformation of rat FR3T3 fibroblasts carrying an activated myc oncogene requires subsequent mutational events. , 1988, Oncogene research.